Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: JOEBT1 who wrote (201)	1/27/1999 5:24:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1475

Thanks, Joe. Good stuff, but I'll consider the source (Investor Relations). What're they going to say?...... "It's crud, but we have it in our 10-K and PRs, so we gotta keep it quiet for a bit"?? ;-) >> He indicated 507 was their most significant development program << Anti-CD40L and CTLA4 have more bucks thrown behind them. Maybe MEDI should sub-license it for some other indications? Or try to do what GNE did with XOMA for anti-CD11a? GNE essentially used XOMA as a CRO, and it seems to have worked great. Perhaps you can provide big incentives to a company that has excess capacity in mfg and clinical/regulatory? Perhaps there's some wheeling and dealing that needs to be thrown at 507 such that it can, if deserving, complicate issues for BGEN, BMY et al.?? >> Only 700 traded all day << "Only"?? Isn't that above average? ;-(